The efficiency of endothelin receptor antagonist bosentan for pulmonary arterial hypertension associated with congenital heart disease: A systematic review and meta-analysis

BACKGROUND: Oral bosentan has been widely applied in pulmonary arterial hypertension associated with congenital heart disease (PAH-CHD). A systemic review and meta-analysis was conducted for a therapeutic evaluation of oral bosentan in both adult and pediatric patients with PAH-CHD. The acute respon...

Descripción completa

Detalles Bibliográficos
Autores principales: Kuang, Hong-Yu, Wu, Yu-Hao, Yi, Qi-Jian, Tian, Jie, Wu, Chun, Shou, We Nian, Lu, Tie-Wei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2018
Materias:
3400
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5882424/
https://www.ncbi.nlm.nih.gov/pubmed/29517668
http://dx.doi.org/10.1097/MD.0000000000010075

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5882424/
https://www.ncbi.nlm.nih.gov/pubmed/29517668
http://dx.doi.org/10.1097/MD.0000000000010075

Ejemplares similares